Search for other papers by Aglaia Kyrilli in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Department of Gynecology and Obstetrics, Copenhagen University Hospital (Hvidovre Hospital), Hvidovre, Denmark
Search for other papers by Sofie Bliddal in
Google Scholar
PubMed
Carelink Nærhospital, Roskilde, Denmark
Search for other papers by Dorthe Hansen Precht in
Google Scholar
PubMed
Institute of Clinical Medicine, Faculty of Health and Clinical Research, Copenhagen University, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Université Libre de Bruxelles (ULB), Brussels, Belgium
Search for other papers by Kris Poppe in
Google Scholar
PubMed
Introduction Thyroid autoimmunity (TAI), defined as the presence of increased levels of circulating thyroid antibodies (anti thyroperoxidase (TPOAb) and/or anti-thyroglobulin (TgAb) antibodies), may be present in up to 1−17% of pregnant women
Search for other papers by Avinaash Maharaj in
Google Scholar
PubMed
Search for other papers by Ruth Kwong in
Google Scholar
PubMed
Search for other papers by Jack Williams in
Google Scholar
PubMed
Search for other papers by Christopher Smith in
Google Scholar
PubMed
Search for other papers by Helen Storr in
Google Scholar
PubMed
Search for other papers by Ruth Krone in
Google Scholar
PubMed
Search for other papers by Debora Braslavsky in
Google Scholar
PubMed
Search for other papers by Maria Clemente in
Google Scholar
PubMed
Search for other papers by Nanik Ram in
Google Scholar
PubMed
Search for other papers by Indraneel Banerjee in
Google Scholar
PubMed
Search for other papers by Semra Çetinkaya in
Google Scholar
PubMed
Search for other papers by Federica Buonocore in
Google Scholar
PubMed
Search for other papers by Tülay Güran in
Google Scholar
PubMed
Search for other papers by John C Achermann in
Google Scholar
PubMed
Search for other papers by Louise Metherell in
Google Scholar
PubMed
Search for other papers by Rathi Prasad in
Google Scholar
PubMed
trimester onwards. Hypospadias is not a reported clinical feature to date. Biochemical evaluations revealed raised basal gonadotrophins (LH and FSH), an exaggerated response to luteinizing hormone releasing hormone (LHRH) stimulation, impaired testosterone
Search for other papers by Ashley N Reeb in
Google Scholar
PubMed
Search for other papers by Andrea Ziegler in
Google Scholar
PubMed
Search for other papers by Reigh-Yi Lin in
Google Scholar
PubMed
differentiation markers thyroglobulin ( TG ), thyroperoxidase ( TPO ), sodium-iodide symporter ( NIS ), or the receptor for thyroid stimulating hormone ( TSHR ) ( Fig. 1B ), confirming the dedifferentiated state of these human FTC cell lines. Figure 1
Search for other papers by Wei Sun in
Google Scholar
PubMed
Search for other papers by Boyuan Zheng in
Google Scholar
PubMed
Search for other papers by Zhihong Wang in
Google Scholar
PubMed
Search for other papers by Wenwu Dong in
Google Scholar
PubMed
Search for other papers by Yuan Qin in
Google Scholar
PubMed
Search for other papers by Hao Zhang in
Google Scholar
PubMed
studies have reported benefits of PCLND in patients with cN0. For example, PCLDN can help to accurately diagnose tumor-node-metastasis (TNM) staging, help decide on the use of thyroid-stimulating hormone (TSH) suppression therapy or radioactive iodine (RAI
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Guangdong Geriatric Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Search for other papers by Qinglei Yin in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Zhou Jin in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Yulin Zhou in
Google Scholar
PubMed
Reproductive Medicine Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Search for other papers by Dalong Song in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Chenyang Fu in
Google Scholar
PubMed
Division of Endocrinology, Department of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Search for other papers by FengJiao Huang in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Shu Wang in
Google Scholar
PubMed
Introduction Graves’ disease (GD) is an autoimmune disorder characterized by the presence of autoantibodies that bind to and stimulate the thyrotropin receptor, resulting in hyperthyroidism and goiter ( 1 ). It is suggested that the
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
of treatment is to replace thyroid function but, in the latter condition, an additional aim is to keep the serum thyroid-stimulating hormone (TSH) at the lower limit of the normal range and possibly below (TSH suppressive therapy) to improve the
Search for other papers by Laszlo Samson in
Google Scholar
PubMed
Doctoral School of Health Sciences, University of Debrecen, Debrecen, Hungary
Search for other papers by Ildiko Hircsu in
Google Scholar
PubMed
Search for other papers by Monika Katko in
Google Scholar
PubMed
Search for other papers by Miklos Bodor in
Google Scholar
PubMed
Search for other papers by Annamaria Gazdag in
Google Scholar
PubMed
Doctoral School of Health Sciences, University of Debrecen, Debrecen, Hungary
Search for other papers by Andrea Anett Gazso in
Google Scholar
PubMed
Search for other papers by Bela Kovacs in
Google Scholar
PubMed
Search for other papers by Janos Posta in
Google Scholar
PubMed
Search for other papers by Eszter Balogh in
Google Scholar
PubMed
Search for other papers by Peter Mocsary in
Google Scholar
PubMed
Search for other papers by Harjit Pal Bhattoa in
Google Scholar
PubMed
Search for other papers by Endre V Nagy in
Google Scholar
PubMed
metabolism: the level of thyroxine-binding globulin increases in response to elevated oestrogen levels, thyroid-stimulating hormone receptors (TSHR) are stimulated by human chorionic gonadotropin, thyroid hormone and iodine are transported towards the foetus
Department of Pediatric Cardiology, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for other papers by Xuechao Jiang in
Google Scholar
PubMed
Search for other papers by Yonghui Wang in
Google Scholar
PubMed
Search for other papers by Xiaoying Li in
Google Scholar
PubMed
Search for other papers by Leqi He in
Google Scholar
PubMed
Search for other papers by Qian Yang in
Google Scholar
PubMed
Search for other papers by Wei Wang in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
Search for other papers by Bingbing Zha in
Google Scholar
PubMed
components of the thyroid, including thyroglobulin (TG), thyroid peroxidase (TPO), and thyroid-stimulating hormone receptor (TSHR) ( 2 , 3 ). TSHR autoantibodies mimic the function of TSH and lead to uncontrolled thyroid hormone production and
Search for other papers by Kinnaree Sorapipatcharoen in
Google Scholar
PubMed
Search for other papers by Thipwimol Tim-Aroon in
Google Scholar
PubMed
Search for other papers by Pat Mahachoklertwattana in
Google Scholar
PubMed
Search for other papers by Wasun Chantratita in
Google Scholar
PubMed
Search for other papers by Nareenart Iemwimangsa in
Google Scholar
PubMed
Search for other papers by Insee Sensorn in
Google Scholar
PubMed
Search for other papers by Bhakbhoom Panthan in
Google Scholar
PubMed
Search for other papers by Poramate Jiaranai in
Google Scholar
PubMed
Search for other papers by Saisuda Noojarern in
Google Scholar
PubMed
Search for other papers by Patcharin Khlairit in
Google Scholar
PubMed
Search for other papers by Sarunyu Pongratanakul in
Google Scholar
PubMed
Search for other papers by Chittiwat Suprasongsin in
Google Scholar
PubMed
Search for other papers by Manassawee Korwutthikulrangsri in
Google Scholar
PubMed
Search for other papers by Chutintorn Sriphrapradang in
Google Scholar
PubMed
Search for other papers by Preamrudee Poomthavorn in
Google Scholar
PubMed
Departments of Pediatrics and Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. CH was diagnosed based on the findings of elevated serum thyroid-stimulating hormone (TSH) and low free thyroxine (FT 4 ) concentrations on
Search for other papers by Camila Aparecida Moma in
Google Scholar
PubMed
Search for other papers by Icléia Siqueira Barreto in
Google Scholar
PubMed
Search for other papers by Ligia Vera Montali Assumpção in
Google Scholar
PubMed
Search for other papers by Denise Engelbrecht Zantut-Wittmann in
Google Scholar
PubMed
still evidence of biochemical and/or structural disease). The incomplete biochemical response was defined as suppressed thyroglobulin (Tg) levels > 1 ng/mL, TSH-stimulated Tg > 10 ng/mL or rising anti-Tg antibody levels in the absence of structural